ExxonMobil, AT&T, Deere & Co, Bristol-Myers Squibb, and Microsoft all offer compelling dividend yields that could boost income in retirement.
Runaway drug spending is costing Americans billions of dollars every year.
Updated results for its clinical-stage hepatitis C drug failed to spark a rally.
New data from its trial of ARC-520 in hepatitis B ignited a rally.
Kite Pharma, Medivation, Inc., and Portola Pharmaceuticals could all have suitors knocking on their door.
Understanding the level of risk in a therapeutic pipeline leads to smarter investing. Our contributors tip you off on where to be wary, and what benchmarks to look for.
With Allergan now in the rearview mirror, Pfizer may seek to the move the needle by acquiring one of these three drug developers.
Whether you want to stay with oncology or try your hand at antivirals or very small medical devices, any one of these three stocks is better than Exelixis.
Fast-growing immuno-oncology and anticoagulant drugs and top-tier financials make this one company investors ought to consider buying.
After Exelexis' recent market beat-down, is it a better buy than the big pharma that fell off a patent cliff?